First-in-Human trial launches for Off-the-Shelf CAR-NK therapy against tough cancers
NCT ID NCT07366658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new cell therapy called NEUK203-13 for people with advanced small cell lung cancer or other neuroendocrine tumors that have not responded to standard treatments. The therapy uses immune cells (NK cells) made from stem cells and engineered to target a protein called DLL3 on cancer cells. The main goal is to check safety and tolerability, while also looking for early signs that the therapy might control tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NEUK203-13 injection (a CAR-NK cell therapy made from stem cells, targeting DLL3 on cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced small cell lung cancer or other neuroendocrine tumors that have stopped responding to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 9 participants, so the main goal is safety, not proof of effectiveness. The therapy may not shrink tumors, and there are risks like cytokine release syndrome (CRS) and nerve-related side effects (ICANS).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital of CICAMS
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- New drug cocktail aims to shrink tough lung cancers
- Experimental drug targets Hard-to-Treat neuroendocrine cancers